Lytix Biopharma are represented by Head of BD until end July (Anders Fugelli), CEO (Unni Hjelmaas), COO (Wenche Marie Olsen) and new Head of BD as of August (Håkan Wickholm). Lytix Biopharma will present the topical infection drug candidate LTX-109 and the cancer immunotherapy drug candidate LTX-315 in the partnering meetings.